These findings indicated that both BRD7 and c-Myc play critical roles in CRC progression and that the BRD7/c-Myc axis could serve as a potential biomarker and therapeutic target for the early diagnosis and treatment of CRC patients. Here, BRD7 is linked to colorectal carcinoma.